Purpose This study evaluated whether a prophylaxis strategy directed by the graft-versus-
host disease (GVHD) biomarker might reduce the 100-day incidence of acute GVHD grades …

Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical
stem cell transplantation. There is no consensus on the optimal graft-versus-host disease …

Because of its potent immunosuppressive yet stem cell–sparing activity, high-dose
cyclophosphamide was tested as sole prophylaxis of graft-versus-host disease (GVHD) after …

Acute graft-versus-host disease (aGVHD) has various risk factors and outcomes. We defined
distinct aGVHD treatment response groups based on response to first-line corticosteroids …

We examined the hypothesis that plasma biomarkers and concomitant clinical findings after
initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease …

One hundred forty-seven consecutive patients with leukemia, myelodysplastic syndrome, or
aplastic anemia were treated by marrow grafts from genotypically HLA-identical siblings (n …

Cyclosporine A (CSA) and methotrexate (MTX) is the standard graft-versus-host disease
(GVHD) prophylaxis regimen for matched sibling donor (MSD) allogeneic hematopoietic cell …

Acute GVHD remains a major cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation (HSCT). In a retrospective analysis, the response of …

Background Acute graft-versus-host disease (GVHD) following allogeneic bone marrow
transplantation remains a serious problem. In a clinical trial, we tested the combination of …

Previous studies of risk factors for acute graft-versus-host disease (GVHD) involved patients
receiving predominantly single-agent prophylaxis. Therefore, a retrospective analysis was …